NCT01122225

Brief Summary

Acute kidney injury (AKI) is a major organ failure in septic shock. Current medical tests (serum creatinine and urea) cannot identify AKI until approximately 48 hours after it occurs. Neutrophil gelatinase-associated lipocalin (NGAL) may be able to predict ischemic AKI more effectively and faster than serum creatinine and urea levels. The purpose of this study is to take a blood sample from patients at admission and then at 24 and 48 hours after to test their plasma for NGAL and compare the NGAL levels to their creatinine and urea levels. The investigators hypothesize that NGAL is an earlier marker to classify the kidney failure as acute tubular necrosis or pre-renal azotemia than creatinine and urea.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2009

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2009

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

May 10, 2010

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 13, 2010

Completed
19 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2010

Completed
Last Updated

May 31, 2010

Status Verified

April 1, 2010

Enrollment Period

10 months

First QC Date

May 10, 2010

Last Update Submit

May 28, 2010

Conditions

Keywords

septic shockmedical intensive care

Study Arms (1)

Septic shock

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients of a medical intensive care presenting with a septic shock

You may qualify if:

  • Patients showing signs of infection and hypotension requiring the use of epinephrine despite of an appropriate fluid challenge.
  • years of age or older

You may not qualify if:

  • Age under 18 years
  • Prisoners or other institutionalized or vulnerable individuals
  • Participation in an interventional clinical study within the previous 30 days

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Reanimation medicale, Hopital Saint-Andre, Bordeaux University Hospital

Bordeaux, Aquitaine, 33000, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood Sample (350 µl) at inclusion and then 24 and 48 hours after

MeSH Terms

Conditions

Acute Kidney InjuryShock, Septic

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesSepsisInfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsShock

Study Officials

  • Fabrice Camou, MD

    University Hospital, Bordeaux

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 10, 2010

First Posted

May 13, 2010

Study Start

July 1, 2009

Primary Completion

May 1, 2010

Study Completion

June 1, 2010

Last Updated

May 31, 2010

Record last verified: 2010-04

Locations